ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 27 of 194 for:    breast,cancer,prevention | Recruiting, Not yet recruiting, Available Studies

Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03404752
Recruitment Status : Recruiting
First Posted : January 19, 2018
Last Update Posted : January 19, 2018
Sponsor:
Collaborator:
QUID-Quality in Drugs and Devices Latin American Consulting SRL
Information provided by (Responsible Party):
Gema Biotech S.A.

Brief Summary:
This is a randomized, multicentre, Phase 3 study. Patients will be randomly assigned to the Study drug or its comparator. The study will be blinded for the staff members in charge of the endpoint assessment.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Peg-Filgrastim Phase 3

Detailed Description:

Eligible patients will be scheduled to receive a chemotherapy regimen with risk of febrile neutropenia ≥20%. Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMA BIOTECH, or Peg-Filgrastim of Roche).

A total of 4 or 6 cycles of chemotherapy supported by Peg-Filgrastim will be administered with an interval of three weeks between each cycle.

Patients will be followed up for 28± 3 days after the last dose of Peg-Filgrastim.

Hematological assessment (Absolute Neutrophil Count [ANC]) will be assessed on day 1 or up to -3 (before administration of anticancer chemotherapy), day 2 or 3 and 5 through 9 of the first cycle, and thereafter every day until post-nadir ANC recovery to ≥ 1.5 x 109/l following each cycle of chemotherapy. In the following cycles, hematological assessment shall be performed on day 1 or up to -3 (before administration of anticancer chemotherapy), on day 2 or 3 and on days 5 and 7. This schedule only applies if the subject did not develop Severe Neutropenia on the previous cycle. If the patient develops Severe Neutropenia on the first cycle or at any cycle, then the schedule corresponding to first cycle shall be followed.

During baseline (before the administration of Peg-Filgrastim), day 5 and day 9 following the first cycle of chemotherapy CD34+ (cluster of differentiation) count will be determined.

The study consists of:

  • Screening (up to 4 weeks)
  • Treatment period (6 cycles each of 3 weeks. i.e. a total of 18 weeks)
  • Follow up period for safety (4 weeks after Peg-Filgrastim last dose)

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Multicenter Clinical Trial to Determine the Efficacy, Safety and Tolerability of Peg-filgrastim (Gema) Compared to Peg-filgrastim (Roche) for Prevention of Chemotherapy Induced Neutropenia in Patients With Breast Cancer
Study Start Date : August 2015
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : December 2018


Arm Intervention/treatment
Experimental: Peg-Neutropine®
Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
Drug: Peg-Filgrastim
Other Names:
  • Peg-Neutropine®
  • Neulastim®

Active Comparator: Neulastim®
Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
Drug: Peg-Filgrastim
Other Names:
  • Peg-Neutropine®
  • Neulastim®




Primary Outcome Measures :
  1. Clinical Efficacy: Duration (in days) of severe neutropenia-DSN [ Time Frame: Day 5 to day 9 of the first cycle ]
    ANC (Absolute Neutrophil Count) < 500/mm3 in the first cycle of chemotherapy.


Secondary Outcome Measures :
  1. Clinical Efficacy: Incidence of severe neutropenia [ Time Frame: Day 5 to Day 21 during 4 - 6 cycles ]
    ANC (Absolute Neutrophil Count) <500/mm3 or 0.5 x 109/l not associated with fever across the cycles

  2. ANC nadir [ Time Frame: Day 5 to Day 21 during 4 - 6 cycles ]
    Determination of ANC decreasing (depth of ANC nadir) and time to the post nadir ANC recovery (ANC ≥ 1500 /mm3)

  3. Incidence of neutropenia [ Time Frame: Day 5 to Day 21 during 4 - 6 cycles ]
    Incidence of Grade 3 neutropenia (ANC <1000 - 500/mm3) . incidence of Febrile Neutropenia-FN [defined as ANC <1000/mm3 or 1.0 x 109/l and a single temperature of >38.3° C (101° F) or a sustained temperature of ≥38° C (100.4° F)] for more than one hour by cycle and across the cycles. incidence of ANC <500/mm3 and body temperature of >38.3°C.

  4. Fever [ Time Frame: Day 5 to Day 21 during 4 - 6 cycles ]
    Incidence of fever (temperature of >38.3° C - 101° F)

  5. infections [ Time Frame: Day 5 to Day 21 during 4 - 6 cycles ]
    Incidence of infections

  6. IV anti-infectives [ Time Frame: Day 5 to Day 21 during 4 - 6 cycles ]
    Incidence of need for IV anti-infectives

  7. Post-chemotherapy hospitalization [ Time Frame: Day 5 to Day 21 during 4 - 6 cycles ]
    Incidence and duration of post-chemotherapy hospitalization

  8. Hospitalization due to neutropenia [ Time Frame: Day 5 to Day 21 during 4 - 6 cycles ]
    Incidence and duration of hospitalization as a result of neutropenia

  9. Mortality [ Time Frame: Day 5 to Day 21 during 4 - 6 cycles ]
    Mortality due to infection

  10. Pharmacodynamics [ Time Frame: Day 5 and 9 of the first cycle ]
    The mobilization of CD34+ cells

  11. Incidence of Adverse Drug Reactions (safety and tolerability) as assessed by CTCAE v4.0 [ Time Frame: Day 5 to Day 21 during 4 - 6 cycles ]
    Frequency of patients who withdraw the study drug due to lack of tolerance Frequency of patients who withdraw the study drug treatment due to any reason Incidence of local tolerability at the injection site

  12. Immunogenicity [ Time Frame: Day 5 and Day 28 of the last cycle ]
    Neutralizing Antibody (NABs) Titer and Binding Antibodies (BABs) to Peg-Filgrastim (anti-rG-CSF [Recombinant Granulocyte-Colony stimulating factors] antibodies greater or equal to a determined concentration expressed in U/mL) will be measured using validated methods



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female patients aged 18 to 70 years old.
  • Patients diagnosed having high risk stage 2 or stage 3 or 4 of breast cancer (by histopathological or cytological diagnosis) and need neoadjuvant, adjuvant chemotherapy, or with metastatic disease.
  • A priori has been decided to be treated with Peg-Filgrastim and subjects eligible for Peg-Filgrastim therapy according to indications and clinical use in the product monograph
  • Patients scheduled to receive 4 or 6 cycles of chemotherapy (Taxane combinations) with prophylactic Peg-Filgrastim at 3 weeks interval. Monoclonal Antibodies in addition to Taxane regimens are permitted.
  • Any acute adverse effects of prior therapy must have resolved to ≤ NCI CTCAE (Version 4.0) grade 1 (excluding alopecia) prior to Day 1 of Cycle 1
  • Eastern Cooperative Oncology Group - ECOG Performance Status 0, 1 or 2 as determined on Day 1 or up to -3 of Cycle 1 prior to administration of chemotherapy
  • Patients must have adequate organ function including the following:

    1. Adequate bone marrow functions, as determined within 3 days prior to administration of chemotherapy on Day 1 of Cycle 1 and as indicated by Hb ≥9,5 g/dl (transfusion permitted to be included in the trial ),WBC (white blood cell) ≥3,5 x 109/l, Absolute neutrophil count (ANC) ≥1.5 x 109/l, Platelets ≥95 x 109/l;
    2. Adequate renal and hepatic function, as determined within 3 days prior to administration of chemotherapy on Day 1 of Cycle 1 and defined as follows,

      1. Hepatic: Bilirubin ≤ 1.5 x the upper limit of normal (ULN) (unless elevation is known to be due to Gilbert's disease), Subjects must also meet one of the following criteria:

        1. Alkaline phosphatase within normal reference range and both AST (aspartate aminotransferase) and ALT (alanine aminotransferase) >2.5 x ULN; or
        2. Alkaline phosphatase <2.5 x ULN and both AST and ALT <1.5 x ULN; or
        3. Alkaline phosphatase <5 x ULN and both AST and ALT within normal reference range;
      2. Renal: Serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≤ 60 ml/min (calculated according to the Cockcroft and Gault formula)
  • Patients of child-bearing potential must have a negative pregnancy test within 3 days prior to the first dose of chemotherapy and at day 1 or up to -3 days of each Cycle) and use at least one form of contraception as approved by the investigator during the study.
  • Life expectancy >6 months

Exclusion Criteria:

Safety of treatment dependent criteria:

  • Presence of any serious concomitant systemic disorders incompatible with the administration of filgrastim, Peg-Filgrastim or any systemic disease that can influence the patient's safety according to doctor's diagnosis.
  • History of hypersensitivity to Peg-Filgrastim, filgrastim or E.coli derived proteins.
  • Serious local infection or active systemic infection within 10 days prior to enrollment or patients who have taken antibiotics within the previous 10 days
  • Pregnant or breast-feeding patients
  • Cardiac insufficiency, cardiomyopathy, significant cardiac dysrhythmia, unstable or advanced ischemic heart disease (NYHA III or IV)
  • Known bleeding disorder
  • Patient known to have HIV, Hepatitis B, Hepatitis C or who have a positive serology for HIV, Hepatitis B or Hepatitis C at screening
  • History or presence of sickle cell disease
  • Concurrent or prior radiotherapy within four weeks of randomization

Criteria dependent on compliance with study procedures, or the evaluation of the response:

  • Unwilling to use a reliable and acceptable contraceptive method throughout the study period (fertile patients only)
  • Treatment with certain other agents to treat the malignant disease
  • Known drug addiction, including alcoholism
  • Treatment with any investigational product within 30 days prior to study drug administration
  • Concurrent prophylactic antibiotics
  • Previous participation in this study.
  • Already involved in another trial.
  • History of bone marrow or stem cell transplantation.
  • Previous therapy should not have included G-CSF (granulocyte-colony stimulating factor)

Previous participation in this study: Subjects who are considered screening failures are allowed to be re-screened, except if have started chemotherapy. In case of re-screening the following assessments and evaluations do not have to be repeated: Demographics, Medical history, HIV, Hepatitis B and C serology.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03404752


Contacts
Contact: Ezequiel Klimovsky, MD 54 11 4952 1360 eklimovsky@quid-consulting.com
Contact: Luciana Frassia 54 11 4952 1360 lfrassia@quid-consulting.com

Locations
Argentina
COIBA Recruiting
Buenos Aires, Bs As, Argentina
Contact: Mirta Varela, MD    54 11 4226 2013    msvarela@fibertel.com.ar   
Sponsors and Collaborators
Gema Biotech S.A.
QUID-Quality in Drugs and Devices Latin American Consulting SRL
Investigators
Study Chair: Ezequiel Klimovsky, MD QUID quality in drugs and devices LATAM consulting SRL

Responsible Party: Gema Biotech S.A.
ClinicalTrials.gov Identifier: NCT03404752     History of Changes
Other Study ID Numbers: GEMPEGFIL001
First Posted: January 19, 2018    Key Record Dates
Last Update Posted: January 19, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Gema Biotech S.A.:
breast cancer
chemotherapy
Neutropenia
Peg-filgrastim
biosimilar

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Neutropenia
Skin Diseases
Agranulocytosis
Leukopenia
Leukocyte Disorders
Hematologic Diseases
Lenograstim
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs